Gilead's hepatitis C franchise breaks out of a rut, but the M&A drumbeat continuesadmin 27th July 2017 Uncategorised 0
Gilead Sciences made an unexpected turnaround in the second quarter, with hepatitis C sales finding firmer ground after a long slog through weak quarters. That doesn’t mean M&A pressure is lapsing, though. As one analyst pointed out, the cash boost gives Gilead even more firepower to make a deal.
More: Gilead's hepatitis C franchise breaks out of a rut, but the M&A drumbeat continues